[
  {
    "ts": null,
    "headline": "Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report?",
    "summary": "Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "url": "https://finnhub.io/api/news?id=2eb03902a87b01b2e87e53d6e119582df46e6c92ab7551def963e78c02fa8d65",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768237805,
      "headline": "Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report?",
      "id": 138078139,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
      "url": "https://finnhub.io/api/news?id=2eb03902a87b01b2e87e53d6e119582df46e6c92ab7551def963e78c02fa8d65"
    }
  },
  {
    "ts": null,
    "headline": "Here’s What Lifted Vertex Pharmaceuticals (VRTX) in Q4",
    "summary": "ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities reported a strong but volatile performance in the fourth quarter, with the S&P 500 Index returning 2.7% while the benchmark Russell Midcap Growth Index declined 3.7%. In this environment, a […]",
    "url": "https://finnhub.io/api/news?id=d3d7566a84a5fd042463b4226e4a44334129dd35a700d426c782cceef94ae84b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768226734,
      "headline": "Here’s What Lifted Vertex Pharmaceuticals (VRTX) in Q4",
      "id": 138072411,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities reported a strong but volatile performance in the fourth quarter, with the S&P 500 Index returning 2.7% while the benchmark Russell Midcap Growth Index declined 3.7%. In this environment, a […]",
      "url": "https://finnhub.io/api/news?id=d3d7566a84a5fd042463b4226e4a44334129dd35a700d426c782cceef94ae84b"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations",
    "summary": "AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings target and the FDA flipped its position on a cell therapy from Atara.",
    "url": "https://finnhub.io/api/news?id=4c5cd43b9789dda93c2e7019c0a76364351620a7132db313a44e9fefec4c074b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768217040,
      "headline": "AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations",
      "id": 138075441,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings target and the FDA flipped its position on a cell therapy from Atara.",
      "url": "https://finnhub.io/api/news?id=4c5cd43b9789dda93c2e7019c0a76364351620a7132db313a44e9fefec4c074b"
    }
  }
]